# The Study is Being Conducted to Evaluate the Safety and Efficacy of XJN010 Nasal Spray in Patients With Parkinson's Disease Experiencing Off Episodes

> **NCT07156773** · PHASE2 · RECRUITING · sponsor: **Guangzhou Novaken Pharm Co., Ltd.** · enrollment: 84 (estimated)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** XJN010 Nasal Spray
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07156773
- **Lead sponsor:** Guangzhou Novaken Pharm Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-03
- **Primary completion:** 2026-03-30
- **Final completion:** 2026-04-30
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2025-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07156773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07156773, "The Study is Being Conducted to Evaluate the Safety and Efficacy of XJN010 Nasal Spray in Patients With Parkinson's Disease Experiencing Off Episodes". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT07156773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*